Skip to main content
Premium Trial:

Request an Annual Quote

Acacia to Spin Out CombiMatrix as Independent Public Company

NEW YORK, Jan. 9 (GenomeWeb News) - Acacia Research said today that its board of directors has approved a plan for its CombiMatrix microarray subsidiary to become an independent public company.

 

Acacia said it expects the transaction to close in the second quarter of 2006, subject to receiving a "satisfactory tax opinion from legal counsel" and other conditions.

 

If these conditions are met, Acacia will redeem all of the issued and outstanding shares of Acacia Research-CombiMatrix common stock, which trades under the ticker symbol CBMX, for all of the common stock of CombiMatrix, which will list its shares for trading on Nasdaq.

 

The spin-out "will benefit both companies by eliminating the risk factors associated with the current capital structure," Paul Ryan, chairman and CEO of Acacia, said in statement. The separation of the two companies is also expected to make the firms more attractive to investors, he said.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.